Forbes -
19 Mar 2013 22:12
Vertex Pharmaceuticals (VRTX) had its price target and estimates increased by J.P. Morgan (JPM) after a discussion with physicians regarding the company's upcoming cystic fibrosis trial. A price target of $86 was set.
Share this Article